Workflow
CGuard® Prime carotid stent system
icon
Search documents
InspireMD Announces the Appointment of Dan Dearen to its Board of Directors
Globenewswire· 2025-09-17 12:00
Company Overview - InspireMD, Inc. is a developer of the CGuard® Prime carotid stent system aimed at preventing strokes [1] - The company is publicly traded on Nasdaq under the ticker symbol NSPR [5] Leadership Appointment - Dan Dearen has been appointed to the Board of Directors, bringing nearly 40 years of experience in the medical device and life sciences sectors [1][2] - His previous roles include President, co-Founder, and Chief Financial Officer of Axonics, Inc., which was acquired by Boston Scientific for $3.7 billion in November 2024 [2][3] Strategic Importance - The appointment of Mr. Dearen is seen as timely as InspireMD continues its U.S. commercial launch of the CGuard Prime stent system [2] - The company aims to lead the carotid intervention market and execute its long-term value-creation strategy [2] Market Potential - Mr. Dearen expressed optimism about InspireMD's potential to change the standard of care in vascular medicine and improve patient outcomes [2] - The company utilizes proprietary MicroNet™ mesh technology to enhance the effectiveness of its carotid stenting products [5]
InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Globenewswire· 2025-08-27 13:00
Core Viewpoint - InspireMD, Inc. is set to present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, highlighting its focus on the CGuard® Prime carotid stent system for stroke prevention [1] Company Overview - InspireMD, Inc. aims to establish its proprietary MicroNet™ mesh technology as the industry standard for carotid stenting, emphasizing superior acute results and long-term stroke-free outcomes [2] - The company's common stock is traded on Nasdaq under the ticker symbol NSPR, and it regularly updates important information for investors on its website [2]
InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors
Globenewswire· 2025-07-31 12:31
Core Viewpoint - InspireMD, Inc. has appointed Raymond W. Cohen to its Board of Directors, bringing over 40 years of experience in medical technology to enhance the company's strategic vision and operational execution [1][2]. Company Overview - InspireMD is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes, utilizing proprietary MicroNet™ mesh technology to achieve superior acute results and long-term outcomes [6]. Leadership Experience - Raymond W. Cohen has a notable track record, having co-founded Axonics, Inc., which went public in 2018 and was acquired by Boston Scientific for $3.7 billion in November 2024 [2]. - Cohen previously served as Chairman of SoniVie Ltd., which was acquired by Boston Scientific for $600 million, and has held leadership roles in various medical technology companies [3][4]. Strategic Goals - The company is shifting its focus towards the commercial launch of the CGuard Prime stent system following its recent PMA approval, with expectations of capturing market share and delivering long-term value [2][5]. - Cohen expressed confidence in InspireMD's potential to lead the U.S. carotid stent market due to its innovative approach and commitment to clinical excellence [5].
InspireMD Announces Combined Financings of $58 Million
Globenewswire· 2025-07-31 12:30
Core Insights - InspireMD, Inc. has raised approximately $58 million through a PIPE financing and warrant exercise, following the FDA's approval of its CGuard® Prime carotid stent system [1][2][3] - The PIPE financing generated gross proceeds of $40.1 million, with participation from existing and new investors, and the exercise of warrants contributed an additional $17.9 million [2][3] - The funds will be utilized for operations including sales and marketing, research and development, and general corporate purposes [4] Financing Details - The PIPE financing involved the issuance of 16,556,184 shares of common stock at a purchase price of $2.42 per share [2] - The transaction is expected to close by August 1, 2025, subject to customary conditions [3] - BofA Securities acted as the exclusive placement agent for the PIPE [4] Strategic Objectives - The CEO of InspireMD stated that the transaction strengthens the company's balance sheet and positions it for rapid commercial growth in the carotid intervention market [3] - The company aims to leverage its proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting [7]